Evidence map›Paper›PMID 42297748›Full record

Trial reportDiabetes, obesity & metabolism2026

Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Albuminuria Irrespective of Baseline HbA1c Levels: A Participant-Level Exploratory Analysis of the Randomised CONFIDENCE Trial.

Janet B McGill, Jennifer B Green, Hiddo J L Heerspink, Johannes F E Mann, Amy K Mottl, Julio Rosenstock, Peter Rossing, Muthiah Vaduganathan, Masaomi Nangaku, Meike Brinker and 6 more

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Janet B McGillDivision of Endocrinology, Metabolism & Lipid Research, Washington University in St. Louis, School of Medicine, St. Louis, Missouri, USA.ORCID https://orcid.org/0000-0002-6228-6521
Jennifer B GreenDivision of Endocrinology, Department of Medicine and Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Hiddo J L HeerspinkDepartment of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.ORCID https://orcid.org/0000-0002-3126-3730
Johannes F E MannKfH Kidney Centre, Munich, Germany.
Amy K MottlUniversity of North Carolina Kidney Center, UNC School of Medicine, Chapel Hill, North Carolina, USA.
Julio RosenstockUniversity of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID https://orcid.org/0000-0001-8324-3275
Peter RossingSteno Diabetes Center Copenhagen, Herlev, Denmark.ORCID https://orcid.org/0000-0002-1531-4294
Muthiah VaduganathanDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0003-0885-1953
Masaomi NangakuDivision of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
Meike BrinkerCardiology and Nephrology Clinical Development, Bayer AG, Wuppertal, Germany.
Charlie ScottClinical Statistics and Analytics, Bayer US LLC, Whippany, New Jersey, USA.
Katja RohwedderGlobal Medical Affairs, Bayer AG, Berlin, Germany.
Li LiGlobal Medical and Evidence, Bayer AG, Berlin, Germany.
Na LiGlobal Medical and Evidence, Bayer Healthcare, Beijing, China.
Margarida SecoGlobal Medical and Evidence, Bayer AG, Lisbon, Portugal.
Rajiv AgarwalDivision of Nephrology, Richard L. Roudebush VA Medical Center, Indianapolis, Indiana, USA.ORCID https://orcid.org/0000-0001-8355-7100

Funding

Bayer AG, Leverkusen, Germany
6 · The paper itself

Abstract

aimsThis prespecified analysis evaluated whether the safety and efficacy of finerenone and a sodium-glucose cotransporter 2 inhibitor (SGLT2i) combination vary by baseline glycated haemoglobin (HbA1c). MATERIALS AND

methodsAdults with type 2 diabetes and a urinary albumin-to-creatinine ratio (UACR) of 100 - < 5000 mg/g, estimated glomerular filtration rate (eGFR) 30-90 mL/min/1.73 m

resultsBaseline HbA1c was available for 781/800 CONFIDENCE participants; baseline HbA1c and eGFR mean values (standard deviation) were 7.3% (1.2%) and 54.2 mL/min/1.73 m

conclusionSimultaneous initiation with finerenone and an SGLT2i reduced UACR compared with monotherapy and was well-tolerated irrespective of HbA1c levels.

Indexed as

AlbuminuriaBenzhydryl CompoundsDiabetes Mellitus, Type 2Diabetic NephropathiesGlucosidesSodium-Glucose Transporter 2 InhibitorsAgedDrug Therapy, CombinationFemaleGlomerular Filtration RateGlycated HemoglobinHumansMaleMiddle AgedNaphthyridinesTreatment OutcomeBenzhydryl CompoundsempagliflozinfinerenoneGlucosidesGlycated Hemoglobinhemoglobin A1c protein, humanNaphthyridinesSodium-Glucose Transporter 2 Inhibitorsalbuminuriachronic kidney diseaseHbA1cSGLT2 inhibitortype 2 diabetes

Identifiers

PMID42297748
PMCPMC13448955

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.